{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T08:28:06Z","timestamp":1720340886861},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12913-017-2401-2","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T12:23:51Z","timestamp":1498739031000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of generic and essential medicines for prevention and treatment of cardiovascular diseases in Portugal"],"prefix":"10.1186","volume":"17","author":[{"given":"Helena","family":"Gama","sequence":"first","affiliation":[]},{"given":"Carla","family":"Torre","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Pedro","family":"Guerreiro","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Suzete","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Lunet","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"2401_CR1","volume-title":"The world medicines situation 2011. Global health trends: global burden of disease and pharmaceutical needs","author":"W Kaplan","year":"2011","unstructured":"Kaplan W, Mathers C. The world medicines situation 2011. Global health trends: global burden of disease and pharmaceutical needs. Geneva: World Health Organization; 2011."},{"key":"2401_CR2","volume-title":"Priority medicines for Europe and the world - 2013 update","author":"W Kaplan","year":"2013","unstructured":"Kaplan W, Wirtz VJ, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority medicines for Europe and the world - 2013 update. Geneva: World Health Organization; 2013."},{"key":"2401_CR3","volume-title":"European cardiovascular disease statistics","author":"M Nichols","year":"2012","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics. Oxford: European Society of Cardiology; 2012."},{"key":"2401_CR4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/01.CIR.102.13.1511","volume":"102","author":"S Capewell","year":"2000","unstructured":"Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation. 2000;102:1511\u20136.","journal-title":"Circulation"},{"key":"2401_CR5","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","volume":"356","author":"ES Ford","year":"2007","unstructured":"Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388\u201398.","journal-title":"N Engl J Med"},{"key":"2401_CR6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.CIR.0000118498.35499.B2","volume":"109","author":"B Unal","year":"2004","unstructured":"Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101\u20137.","journal-title":"Circulation"},{"key":"2401_CR7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1747-4949.2011.00613.x","volume":"7","author":"E Heeley","year":"2011","unstructured":"Heeley E, Anderson C, Patel A, et al. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. Int J Stroke. 2011;7:649\u201354.","journal-title":"Int J Stroke"},{"key":"2401_CR8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281\u2013357.","journal-title":"J Hypertens"},{"key":"2401_CR9","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/2047487313497864","volume":"21","author":"F Araujo","year":"2014","unstructured":"Araujo F, Gouvinhas C, Fontes F, La Vecchia C, Azevedo A, Lunet N. Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980-2010). Eur J Prev Cardiol. 2014;21:1004\u201317.","journal-title":"Eur J Prev Cardiol"},{"key":"2401_CR10","volume-title":"Portugal-Doen\u00e7as C\u00e9rebro-Cardiovasculares em n\u00fameros","author":"RC Ferreira","year":"2013","unstructured":"Ferreira RC, Neves RC, Rodrigues V. Portugal-Doen\u00e7as C\u00e9rebro-Cardiovasculares em n\u00fameros. Dire\u00e7\u00e3o Geral de Sa\u00fade: Lisboa; 2013."},{"key":"2401_CR11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/08037051.2012.666380","volume":"21","author":"M Pereira","year":"2012","unstructured":"Pereira M, Carreira H, Vales C, Rocha V, Azevedo A, Lunet N. Trends in hypertension prevalence (1990-2005) and mean blood pressure (1975-2005) in Portugal: a systematic review. Blood Press. 2012;21:220\u20136.","journal-title":"Blood Press"},{"key":"2401_CR12","volume-title":"Medicamentos do Aparelho Cardiovascular: Uma an\u00e1lise dos padr\u00f5es de utiliza\u00e7\u00e3o e despesa em Portugal Continental entre 2000 e 2011","author":"C Furtado","year":"2013","unstructured":"Furtado C. Medicamentos do Aparelho Cardiovascular: Uma an\u00e1lise dos padr\u00f5es de utiliza\u00e7\u00e3o e despesa em Portugal Continental entre 2000 e 2011. INFARMED: Lisboa; 2013."},{"key":"2401_CR13","volume-title":"Monitoriza\u00e7\u00e3o do Mercado de Medicamentos em Ambulat\u00f3rio Maio 2013","author":"Gabinete de Estudos e Projetos do INFARMED I.P","year":"2013","unstructured":"Gabinete de Estudos e Projetos do INFARMED I.P. Monitoriza\u00e7\u00e3o do Mercado de Medicamentos em Ambulat\u00f3rio Maio 2013. Lisboa: INFARMED; 2013."},{"key":"2401_CR14","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999\u20133054.","journal-title":"Eur Heart J"},{"key":"2401_CR15","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1177\/2047487313494580","volume":"21","author":"M Pereira","year":"2014","unstructured":"Pereira M, Araujo C, Dias P, et al. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study. Eur J Prev Cardiol. 2014;21:1401\u20138.","journal-title":"Eur J Prev Cardiol"},{"key":"2401_CR16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569\u2013619.","journal-title":"Eur Heart J"},{"key":"2401_CR17","first-page":"1465","volume":"28","author":"JF Santos","year":"2009","unstructured":"Santos JF, Aguiar C, Gavina C, Azevedo P, Morais J. Portuguese registry of acute coronary syndromes: seven years of activity. Rev Port Cardiol. 2009;28:1465\u2013500.","journal-title":"Rev Port Cardiol"},{"key":"2401_CR18","unstructured":"European Commission: Commission Staff Working Document: Investing in Health. Brussels. 2013. \nhttp:\/\/ec.europa.eu\/health\/strategy\/policy\/index_en.htm\n\n. Accessed 27 June 2017."},{"key":"2401_CR19","volume-title":"EU Pharmaceutical expenditure forecast","author":"L Briol","year":"2012","unstructured":"Briol L. EU Pharmaceutical expenditure forecast. Luxembourg: European Commission; 2012."},{"key":"2401_CR20","unstructured":"Barros P, Machado S, Sim\u00f5es J. Health systems in transition: Portugal health system review, vol. 13. Geneva: World Health Organization; 2011. p. 4."},{"key":"2401_CR21","unstructured":"Sakellarides C, Castelo-Branco L, Barbosa P, Azevedo H. The impact of the financial crisis on the health system and health in Portugal. Copenhagen: World Health Organization; 2014."},{"key":"2401_CR22","unstructured":"Department of Essential Medicines and Pharmaceutical Policies. Fact book on WHO level I - Indicators 2007. Report n. WHO\/EMP\/MPC\/2010. Copenhagen: World Health Organization; 2009."},{"key":"2401_CR23","volume-title":"18th list of essential medicines","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 18th list of essential medicines. Geneve: WHO; 2013."},{"key":"2401_CR24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2125.2002.01690.x","volume":"54","author":"B Begaud","year":"2002","unstructured":"Begaud B, Bergman U, Eichler HG, Leufkens HG, Meier PJ. Drug reimbursement: indicators of inappropriate resource allocation. Br J Clin Pharmacol. 2002;54:528\u201334.","journal-title":"Br J Clin Pharmacol"},{"key":"2401_CR25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bmj.321.7272.1341","volume":"321","author":"D Gilbert","year":"2000","unstructured":"Gilbert D, Walley T, New B. Lifestyle medicines. BMJ. 2000;321:1341\u20134.","journal-title":"BMJ"},{"key":"2401_CR26","doi-asserted-by":"crossref","first-page":"e1000194","DOI":"10.1371\/journal.pmed.1000194","volume":"6","author":"TP Staa van","year":"2009","unstructured":"van Staa TP, Leufkens HG, Zhang B, Smeeth L. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med. 2009;6:e1000194.","journal-title":"PLoS Med"},{"key":"2401_CR27","unstructured":"DGS. Normas clinicas. Available from: \nhttps:\/\/www.dgs.pt\/normas-orientacoes-e-informacoes.aspx\n\n. Accessed 27 June 2017."},{"key":"2401_CR28","volume-title":"Guidelines for ATC classification","author":"WHO collaborating centre for drug statistics methodology","year":"1990","unstructured":"WHO collaborating centre for drug statistics methodology. Guidelines for ATC classification. Oslo: Nordic Council on Medicines; 1990."},{"key":"2401_CR29","unstructured":"WHO. Essential medicines Sweden. Available from: \nhttp:\/\/www.who.int\/selection_medicines\/country_lists\/swe\/en\/index.html\n\n. Accessed 27 June 2017."},{"key":"2401_CR30","unstructured":"WHO. Essential medicines selection. Available from: \nhttp:\/\/www.who.int\/selection_medicines\/country_lists\/en\/\n\n. Accessed 27 June 2017."},{"key":"2401_CR31","unstructured":"Decree-Law 271\/2002 from 2 December. Portuguese Health Ministry. Di\u00e1rio da Rep\u00fablica n.278-S\u00e9rie I-A."},{"key":"2401_CR32","unstructured":"Law 11\/2012 from 8 March. Portuguese Republic. Di\u00e1rio da Rep\u00fablica n. 49\/2012-S\u00e9rie I."},{"key":"2401_CR33","volume-title":"Plano Nacional de Sa\u00fade 2012-2016","author":"F George","year":"2013","unstructured":"George F. Plano Nacional de Sa\u00fade 2012-2016. Lisboa: Dire\u00e7\u00e3o Geral de Sa\u00fade; 2013."},{"key":"2401_CR34","unstructured":"Bongers F, Carradinha H. How to increase patient access to generic medicines in European healthcare systems: European Generic Medicines Association; 2009."},{"key":"2401_CR35","unstructured":"OECD\/EU. Health at a glance: Europe 2016. Paris: OECD Publishing; 2016."},{"key":"2401_CR36","first-page":"92","volume":"28","author":"A Magalh\u00e3es","year":"2014","unstructured":"Magalh\u00e3es A, Lunet N, Silva S. Representa\u00e7\u00f5es sociais de professores sobre o uso racional de medicamentos. Arq Med. 2014;28:92\u20138.","journal-title":"Arq Med"},{"key":"2401_CR37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1742-7843.2011.00682.x","volume":"108","author":"LL Gustafsson","year":"2011","unstructured":"Gustafsson LL, Wettermark B, Godman B, et al. The \u2018wise list\u2019- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224\u201333.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2401_CR38","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de utilizaci\u00f3n de medicamientos. In: AEMPS, editor. Madrid. 2014."},{"key":"2401_CR39","unstructured":"Smith O. Prescription cost analysis in England 2012. In: hscic, editor. London. 2013."},{"key":"2401_CR40","unstructured":"Sakshaug S. Drug consumption in Norway 2008-2012. In: FHI, editor. Oslo. 2013."},{"key":"2401_CR41","volume-title":"L'uso dei Farmaci in Italia - Rapporto Nazionale Anno 2012","author":"L Pani","year":"2013","unstructured":"Pani L. L'uso dei Farmaci in Italia - Rapporto Nazionale Anno 2012. Roma: AIFA; 2013."},{"key":"2401_CR42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1403494812459623","volume":"40","author":"G Ringb\u00e4ck","year":"2012","unstructured":"Ringb\u00e4ck G. Prescription drugs: health in Sweden: the National Public Health Report 2012. Chapter 18. Scand J Public Health. 2012;40:293\u2013304.","journal-title":"Scand J Public Health"},{"key":"2401_CR43","volume-title":"Abordagem terap\u00eautica da Hipertens\u00e3o Arterial","author":"F George","year":"2013","unstructured":"George F. Abordagem terap\u00eautica da Hipertens\u00e3o Arterial. Lisboa: DGS; 2013."},{"key":"2401_CR44","first-page":"132","volume":"23","author":"C Torre","year":"2014","unstructured":"Torre C, Guerreiro J, Gomes M, Costa S. Do rational use meet reality in a country under financial assistance program for cost-saving expenditures? The two sides of the Portuguese coin. Pharmacoepidemiol Drug Saf. 2014;23:132\u20133.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2401_CR45","volume-title":"Medveten l\u00e4kemedelsbehandling f\u00f6r st\u00f6rsta patientnytta","author":"K Listan","year":"2011","unstructured":"Listan K. Medveten l\u00e4kemedelsbehandling f\u00f6r st\u00f6rsta patientnytta. Stockolm: Stockholms l\u00e4ns l\u00e4kemedelskommitt\u00e9; 2011."},{"key":"2401_CR46","volume-title":"Medveten l\u00e4kemedels vid vanliga sjukdomar","author":"K Listan","year":"2004","unstructured":"Listan K. Medveten l\u00e4kemedels vid vanliga sjukdomar. Stockholm: Stockholms l\u00e4ns landsting; 2004."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-017-2401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T12:24:13Z","timestamp":1498739053000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-017-2401-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2401"],"URL":"https:\/\/doi.org\/10.1186\/s12913-017-2401-2","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]},"article-number":"449"}}